Cancer Genetics to Buy Gentris, a US-China Genomics CRO

Cancer Genetics, a diagnostics company specializing in cancer, signed a non-binding Letter of Intent to acquire Gentris Corporation, which provides pharmacogenomics, biomarker and biorepository services. Gentris is currently building a US FDA-compliant lab in Shanghai’s Zhangjiang Hi-Tech Park. The purchase price for Gentris is set at $4.75 million, comprised of $3.25 million in cash and $1.5 million in CGI stock. An additional $1.5 million of performance-based earnouts are also available. More details.... Stock Symbol: (NSDQ: CGIX) Share this with colleagues: // //